These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36345508)

  • 1. Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review.
    Cepero A; Luque C; Cabeza L; Perazzoli G; Quiñonero F; Mesas C; Melguizo C; Prados J
    Int J Nanomedicine; 2022; 17():5065-5080. PubMed ID: 36345508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.
    Fakhri S; Moradi SZ; Faraji F; Farhadi T; Hesami O; Iranpanah A; Webber K; Bishayee A
    Cancer Metastasis Rev; 2023 Sep; 42(3):959-1020. PubMed ID: 37505336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer.
    Grifantini R; Taranta M; Gherardini L; Naldi I; Parri M; Grandi A; Giannetti A; Tombelli S; Lucarini G; Ricotti L; Campagnoli S; De Camilli E; Pelosi G; Baldini F; Menciassi A; Viale G; Pileri P; Cinti C
    J Control Release; 2018 Jun; 280():76-86. PubMed ID: 29733876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LGR5 as a Therapeutic Target of Antibody-Functionalized Biomimetic Magnetoliposomes for Colon Cancer Therapy.
    Cepero A; Jiménez-Carretero M; Jabalera Y; Gago L; Luque C; Cabeza L; Melguizo C; Jimenez-Lopez C; Prados J
    Int J Nanomedicine; 2024; 19():1843-1865. PubMed ID: 38414530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts.
    Xu J; Zhang G; Luo X; Wang D; Zhou W; Zhang Y; Zhang W; Chen J; Meng Q; Chen E; Chen H; Song Z
    Theranostics; 2021; 11(5):2475-2489. PubMed ID: 33500737
    [No Abstract]   [Full Text] [Related]  

  • 6. Micelles as potential drug delivery systems for colorectal cancer treatment.
    Fatfat Z; Fatfat M; Gali-Muhtasib H
    World J Gastroenterol; 2022 Jul; 28(25):2867-2880. PubMed ID: 35978871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer.
    Watkins D; Cunningham D
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S47-52. PubMed ID: 18021487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted nanoparticles for colorectal cancer.
    Cisterna BA; Kamaly N; Choi WI; Tavakkoli A; Farokhzad OC; Vilos C
    Nanomedicine (Lond); 2016 Sep; 11(18):2443-56. PubMed ID: 27529192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Getting into the colon: approaches to target colorectal cancer.
    Patel MM
    Expert Opin Drug Deliv; 2014 Sep; 11(9):1343-50. PubMed ID: 24898947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Potential of Polyphenols and their Nanoformulations in the Treatment of Colorectal Cancer.
    Khan SH; Alhumaydhi FA; Khan MA; Younus H
    Anticancer Agents Med Chem; 2021 Oct; 21(16):2117-2129. PubMed ID: 33390126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
    Cercek A; Saltz LB
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal cancer management: strategies in drug delivery.
    Singh P; Waghambare P; Khan TA; Omri A
    Expert Opin Drug Deliv; 2022 Jun; 19(6):653-670. PubMed ID: 35656670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Trends in Liposome-based Drug Delivery in Colorectal Cancer.
    Krajewska JB; Bartoszek A; Fichna J
    Mini Rev Med Chem; 2019; 19(1):3-11. PubMed ID: 30179131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.
    Shapira S; Lisiansky V; Arber N; Kraus S
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S67-77. PubMed ID: 20374033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies in the treatment of colorectal cancers.
    Alekshun T; Garrett C
    Cancer Control; 2005 Apr; 12(2):105-10. PubMed ID: 15855893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.
    Satake H; Kagawa Y; Shinozaki E; Tanizawa Y; Jin L; Cai Z; Makiyama A
    Adv Ther; 2022 Jun; 39(6):2596-2613. PubMed ID: 35384550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.
    Krishnaiah YS; Khan MA
    Pharm Dev Technol; 2012; 17(5):521-40. PubMed ID: 22681390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.